TEVA(US:TEVA) Globenewswire·2025-09-21 02:16Core Insights - Teva Pharmaceuticals presented data showing that patients using AUSTEDO XR reported improved social and emotional well-being due to reduced movement symptoms associated with tardive dyskinesia (TD) [1][3][9] - The survey highlighted high patient satisfaction with AUSTEDO XR, with over 96% of participants finding it easy to take and 96% expressing interest in continuing treatment [3][9][10] Group 1: Patient Experience and Survey Results - The noninterventional survey included 209 participants with TD, revealing that over 94% reported improvement in movement symptoms after treatment with AUSTEDO XR [2][9] - More than 77% of patients agreed that the reduction in movements led to greater comfort in social settings and improved emotional well-being [10] - The survey indicated that 91% of patients with prior valbenazine use and 89% of de novo patients reported overall satisfaction with AUSTEDO XR [10] Group 2: Product Information - AUSTEDO XR is the first vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. FDA for treating TD and chorea associated with Huntington's disease [6][7] - AUSTEDO XR is a once-daily formulation, enhancing patient compliance and convenience [6] Group 3: Company Commitment - Teva emphasizes its responsibility to understand the lived experiences of patients with TD and aims to innovate treatments that restore freedom and quality of life [2][23]